NeuroBo Pharmaceuticals I... (NRBO)
2.36
0.01 (0.43%)
At close: Nov 27, 2024, 9:00 PM
undefined% (undefined)
| Bid | 2.31 |
| Market Cap | 20.33M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -4.29 |
| PE Ratio (ttm) | -0.55 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 2.68 |
| Volume | 12,978 |
| Avg. Volume (20D) | 45,277 |
| Open | 2.42 |
| Previous Close | 2.35 |
| Day's Range | 2.33 - 2.44 |
| 52-Week Range | 2.08 - 6.75 |
| Beta | undefined |
About NRBO
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative, infectious, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which is in Phase 2/3 clinical trials to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify ...
Industry Biotechnology
Sector Healthcare
IPO Date Aug 5, 2016
Employees 8
Stock Exchange NASDAQ
Ticker Symbol NRBO
Website https://www.neurobopharma.com
Analyst Forecast
According to 1 analyst ratings, the average rating for NRBO stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 323.73% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
